COMPARATIVE ADHERENCE TRAJECTORIES OF ORAL FINGOLIMOD AND INJECTABLE DISEASE MODIFYING AGENTS IN MULTIPLE SCLEROSIS

被引：0
|
作者：
Earla, J. R. [1 ]
Hutton, G. J. [2 ]
Thornton, J. D. [1 ]
Chen, H. [1 ]
Johnson, M. L. [1 ]
Aparasu, R. [1 ]
机构：
[1] Univ Houston, Houston, TX USA
[2] Baylor Coll Med, Med Ctr, McNair Campus, Houston, TX 77030 USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND104
引用
收藏
页码：S279 / S279
页数：1
相关论文
共 50 条
  • [41] Oral Disease-Modifying Therapies for Multiple Sclerosis
    Kim, Woojun
    Zandona, Manuella Edler
    Kim, Su-Hyun
    Kim, Ho Jin
    JOURNAL OF CLINICAL NEUROLOGY, 2015, 11 (01): : 9 - 19
  • [42] Adherence to Disease-Modifying Agents among Patients with Multiple Sclerosis: 5 Year Prospective Study
    Cerghet, Mirela
    Elias, Stanton
    Dobie, Liz
    Salloum, Ramzi
    Elston-Lafata, Jennifer
    Schultz, Lonni
    NEUROLOGY, 2011, 76 (09) : A72 - A73
  • [43] Measuring adherence and persistence to disease-modifying agents among patients with relapsing remitting multiple sclerosis
    Lafata, Jennifer Elston
    Cerghet, Mirela
    Dobie, Elizabeth
    Schultz, Lonni
    Tunceli, Kaan
    Reuther, Jacqueline
    Elias, Stanton
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2008, 48 (06) : 752 - 757
  • [44] Persistence and adherence of fingolimod compared with other disease modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis
    Bergvall, N.
    Lahoz, R.
    Agashivala, N.
    Pradhan, A.
    Capkun-Niggli, G.
    Korn, J. R.
    Petrilla, A. A.
    Karkare, S. U.
    McGuiness, C. Balderston
    Makin, C.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 520 - 521
  • [45] Nocebo in multiple sclerosis trials: a meta-analysis on oral and newer injectable disease-modifying treatments
    Gklinos, P.
    Papadopoulos, D.
    Mitsikostas, D. D.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 522 - 522
  • [46] Characteristics of Poor Adherence to the Injectable Disease-Modifying Therapies in Multiple Sclerosis: A Cross-Canada Prospective Study
    McKay, Kyla
    Tremlett, Helen
    Fisk, John
    Patten, Scott
    Fiest, Kirsten
    Berrigan, Lindsay
    Campbell, Trudy
    Marrie, Ruth-Ann
    NEUROLOGY, 2016, 86
  • [47] Nocebo in multiple sclerosis trials: A meta-analysis on oral and newer injectable disease-modifying treatments
    Gklinos, Panagiotis
    Papadopoulos, Dimitrios
    Mitsikostas, Dimos D.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 36
  • [48] CHARACTERISTICS OF PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS TAKING INJECTABLE AND ORAL DISEASE MODIFYING TREATMENTS IN THE UNITED STATES
    Narayanan, S.
    O'Meara, P.
    White, J.
    Chan, J.
    Gabriele, S.
    VALUE IN HEALTH, 2014, 17 (07) : A404 - A404
  • [49] Prescribing of disease modifying agents in older adults with multiple sclerosis
    Talwar, Ashna
    Earla, Jagadeswara R.
    Hutton, George J.
    Aparasu, Rajender R.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 57
  • [50] Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis
    Zanga, Gisela
    Drzewiscki, Estefania
    Tagliani, Paula
    Smietniansky, Maximiliano
    Rojas, Maria M. Esnaola y
    Caruso, Diego
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
12345